Adebrelimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Adebrelimab
- Adebelimab (SHR-1316)
- adebelimab shr 1316
- adebrelimab
- Adebrelimab
- Adebrelimab (PD-L1 inhibitor)
- adebrelimab [INN]
- Adebrelimab [WHO-DD]
- Adebrelimab injection
- Adebrelimab Injection
- adebrelimab inn
- adebrelimab who dd
- anti pd l1 monoclonal antibody shr 1316
- ANTI-PD-L1 MONOCLONAL ANTIBODY SHR-1316
- hti 1088
- HTI-1088
- IMMUNOGLOBULIN G4 (52-GLYCINE,57-PHENYLALANINE,227-PROLINE,233-ALANINE,234-ALANINE), ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS MONOCLONAL SHR-1316 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL SHR-1316 .KAPPA.-CHAIN (85-GLUTAMIC ACID), DIMER
- immunoglobulin g4 52 glycine 57 phenylalanine 227 proline 233 alanine 234 alanine anti human programmed cell death protein 1 human mus musculus monoclonal shr 1316 gamma 4 chain disulfide with human mus musculus monoclonal shr 1316 kappa chain 85 glutamic acid dimer
- shr 1316
- Shr-1316
- SHR-1316
- SHR-1316 Injection
- CAS registry numbers
- 2247114-85-6
- ChEMBL ID
- CHEMBL4297828
- FDA ingredient codes (UNII)
- 1XBY50W1OX
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- adebrelimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Binding
- Action type
- Binding
- Target
- programmed cell death 1 ligand 1
- Gene symbol
- programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
- Action type
- Inhibitor
- Target
- Programmed cell death 1 ligand 1
- Protein identifier
- Q9NZQ7
Open Targets mechanisms
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
- Action type
- Inhibitor
- Target
- Programmed cell death 1 ligand 1
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003893
- Subject identifier
- D010051
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Rectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000657
- Subject identifier
- D012004
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001961
- Subject identifier
- D018281
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002974
- Subject identifier
- D002583
- Condition
- Biliary Tract Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0003060
- Subject identifier
- D001661
- Condition
- Adenocarcinoma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0003219
- Subject identifier
- D000230
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007576
- Subject identifier
- D004938
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition
- Nasopharyngeal Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0015459
- Subject identifier
- D000077274
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000199
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005221
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000657
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001901
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001961
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000544
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002108
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002120
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002691
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003059
- Highest recorded phase
- 1
And 48 more, listed on the interactive page.
- Event
- alanine aminotransferase increased
- Reports
- 2
- Reporting signal score
- 6.14689
- Event
- aspartate aminotransferase increased
- Reports
- 2
- Reporting signal score
- 6.37947
- Event
- cerebral radiation injury
- Reports
- 1
- Reporting signal score
- 11.1818
- Event
- endocrine disorder
- Reports
- 1
- Reporting signal score
- 6.78159
- Event
- fatigue
- Reports
- 4
- Reporting signal score
- 8.49937
- Event
- leukopenia
- Reports
- 3
- Reporting signal score
- 11.4774
- Event
- pancreatic disorder
- Reports
- 1
- Reporting signal score
- 5.84046
- Event
- pneumonitis
- Reports
- 2
- Reporting signal score
- 8.35376
- Event
- rash
- Reports
- 3
- Reporting signal score
- 6.34669
- Event
- thrombocytopenia
- Reports
- 3
- Reporting signal score
- 9.10317
- Event
- vomiting
- Reports
- 3
- Reporting signal score
- 6.08738
- NCT03133247
- NCT03474289
- NCT04979390
- NCT05794477
- NCT05942378
- NCT06332170
- NCT06336707
- NCT06385678
- NCT06439589
- NCT03711305
- NCT04041011
- NCT04400188
- NCT04647357
- NCT06236997
- NCT06306560
- NCT06332950
- NCT06483282
- NCT03732508
- NCT03995472
- NCT05082545
- NCT06181032
- NCT04303988
- NCT06149130
- NCT06165900
- NCT06222879
And 45 more, listed on the interactive page.
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (316)
- A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.
- A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
- A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
- A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
- A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
- A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
- A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
- A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
- A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years
- A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
- A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer
- A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer
- A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
- A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
- A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
- A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
In development for (28)
- Biliary tract cancer Phase 2
- Breast cancer Phase 2
- Cancer Phase 1
- Cervical cancer Phase 2
- Cholangiocarcinoma Phase 2
- Colorectal cancer Phase 1
- Esophageal cancer Phase 2
- Esophageal squamous cell carcinoma Phase 2
- Exocrine pancreatic carcinoma Phase 2
- Gastric adenocarcinoma Phase 2
- Gastric cancer Phase 2
- Gastroesophageal junction adenocarcinoma Phase 2
- Head and neck squamous cell carcinoma Phase 2
- Hepatocellular carcinoma Phase 2
- Intrahepatic cholangiocarcinoma Phase 2
- Malignant pancreatic neoplasm Phase 2
- Nasopharyngeal carcinoma Phase 2
- Neoplasm Phase 1
- Neuroendocrine neoplasm Phase 2
- Non-small cell lung carcinoma Phase 2
Targets (1)
- CD274 Programmed cell death 1 ligand 1 inhibitor